尽管在过去10年里,有关非小细胞性肺癌(NSCLC)的肿瘤内科治疗已在多个方面取得了令人欣喜的进展,但至今其治疗效果仍然无法令人满意。一般而言,大约60％～70％左右的NSCLC从起病即为进展期肺癌(advanced NSCLC),即指局部病变侵袭广泛(locally advanced),无法依靠手术整体切除来根治或已经发生远处转移(metastatic)的状态;对此,以放、化疗为主的综合治疗毫无疑问成为这部分患者目前的主要治疗 Although oncological treatments for non-small cell lung cancer (NSCLC) have made gratifying advances in many areas over the past decade, their treatment has so far failed to provide satisfactory results. In general, around 60% to 70% of NSCLC are advanced advanced lung cancers from onset, which means locally advanced lesions that can not be cured by radical resection or have metastasized to distant metastases (metastatic) state; In this regard, radiotherapy, chemotherapy-based comprehensive treatment undoubtedly become the current part of the patient’s main treatment